Essential thrombocythemia is a clonal myeloproliferative neoplasm characterized by an elevated platelet count, the potential for both microvascular and macrovascular sequelae, and a risk for transformation to myelofibrosis or acute myeloid leukemia.
Introduction
Thrombocythemia, or elevation in platelet count (i.e. greater than 450 × 10 (9)/L), is a common observation for internists and hematologists alike. Causes may be secondary or "acquired" in contrast to primary thrombocythemia, meaning that the pathogenesis lies within the abnormal marrow itself. Essential thrombocythemia (ET), one of the myeloproliferative neoplasms (MPNs), is an aberration within the bone marrow and its microenvironment leading to clonal proliferation of the megakaryocytic lineage within the marrow and, ultimately, to peripheral blood thrombocythemia. Unlike secondary thrombocythemia, ET is associated with thrombotic and hemorrhagic complications and requires systemic medical therapy in high-risk patients. In this brief article, we discuss the diagnostic strategy of thrombocytosis with particular attention paid to essential thrombocythemia. Subsequently, the clinical manifestations of ET are examined and the assessment of disease burden is reviewed. The history of therapeutics for ET is reviewed with consideration to the current rationale for therapeutic decision-making.
Uncovering the etiology
Elucidating the etiology of thrombocythemia is of utmost importance prior to any therapeutic decision-making. Certainly, clonal bone marrow diseases such MPNs should be considered. However, such a diagnosis can only be considered after eliminating secondary contributions to the elevated platelet count. Many chronic and acute processes cause stimulation and up-regulation of bone marrow stem cells including infection, malignancy, iron deficiency, prior splenectomy, and recent trauma or surgery. (see Table 1 ). A careful examination of iron status, inflammatory markers, and age appropriate malignancy screen is imperative. History and physical exam, such as a history of gastrointestinal bleeding, rheumatologic disease or the presence of splenomegaly on exam can lend clues as to underlying etiologies. Once secondary causes are excluded, evaluation for an underlying clonal myeloproliferative disorder can commence.
Establishing a diagnosis
MPNs such as ET, polycythemia vera (PV), and myelofibrosis (MF) are Philadelphia negative clonal disorders of the bone marrow 1 . When attempting to establish a diagnosis of MPN, mutational status can be quite helpful 2 . In 2005, a landmark discovery identified a gain of function mutation, JAKV617F, as being an essential mutational driver in many MPNs [3] [4] [5] . In ET, approximately 50% of patients will harbor the JAKV617F mutation. PCR based assays for the JAK2 mutation, from either peripheral blood or marrow, are commercially available. Since the JAKV617F discovery, other molecular breakthroughs have contributed not only to our knowledge of pathogenesis in MPNs but also how we diagnose them. In the majority of JAKV617F wild type patients, the CALR (calreticulin gene) mutation 6 may be detected and now is a widely available assay. Additionally, MPL (myeloproliferative leukemia gene) mutations are detected in a small percentage (<5%) of those afflicted with ET 7, 8 . Although mutation analysis is critical for the evaluation of a suspected MPN, it is not sufficient for diagnosis. A bone marrow biopsy must be obtained and possess features consistent with ET, such as megakaryocytic hyperplasia. Additionally, assessment of cytogenetics, baseline karyotype, reticulin fibrosis, and blast percentage should be performed. Mutational status for other myeloid diseases must be evaluated and negative including the BCR-ABL, i.e. "the Philadelphia chromosome", and fluorescence in situ hybridization (FISH) for myelodysplastic syndrome (MDS) panel to exclude the diagnosis of CML and MDS, respectively (see Table 2) 2 .
Assessing symptom burden
The presentation of MPN may be quite variable. A large proportion of those afflicted with ET are completely asymptomatic at presentation. Unfortunately, approximately 50% of patients with ET do possess some form of systemic manifestation of the disease and experience a substantial impact on their quality of life 9 . Common symptoms may include those from microvascular complications such as headache, dizziness, paresthesia, livedo reticularis, erythromelalgia, and visual changes. Others may present with the more dreaded macrovascular complications such as myocardial infarction, stroke, or pulmonary embolus. Additionally, constitutional symptoms may be prevalent with symptoms of fatigue, night sweats, and weight loss; particularly in those transitioning to a more 10 . Due to this effort, the MPN-Symptom Assessment Form (SAF) 11 is now available and validated for use in this patient population and has proven to be an invaluable tool in the assessment and management of ET. Though use of the MPN-SAF a subset of ET patients were identified who possess a significant symptomatic burden, with fatigue and microvascular complications being the most prevalent 10 . For the treating clinician, the MPN-SAF can be utilized to assess baseline symptomatology and help guide initial therapeutic decision-making as well as gauge subsequent response to therapy.
Risk assessment
Deciding when to initiate therapy in ET may be complex and represents a unique challenge in the treatment of MPNs. A thrombotic risk assessment is necessary to evaluate whether initiation of cytoreduction is warranted 12, 13 . The presence of high-risk features 14 , such as age greater than 60 years and a prior history of thrombosis, is predictive of future complications and generally prompts the clinician to employ cytoreduction. Additionally, concurrent cardiovascular risk factors 15 , JAK V617F mutational status and allelic burden 16, 17 , and the presence of leukocytosis 18 may increase the thrombotic risk potential and contribute to a clinician's decision to initiate therapy. The presence of a heavy symptom burden may also provide more impetus to employ cytoreduction in afflicted patients who are otherwise in a low risk category. An international prognostic model for ET was developed in 2012 by Passamonti et al. and is helpful to ascertain risk and give valuable prognostic information to the treating physician (see Table 3 ) 13 . The treatment goal is improvement in disease related symptoms in addition to normalization of the platelet count to decrease thrombotic risk potential. Typically, the minimal effective dose is utilized to limit treatment-associated toxicity. In those with low-risk asymptomatic disease, simple observation is appropriate.
Initial systemic therapy
In 2004, a European group investigated the use of aspirin for the prevention of thrombotic complications in PV and found that daily low dose aspirin can safely prevent thrombotic complications in those who have no contraindications to such treatment 19 . Since this landmark study, it is standard practice to administer daily low dose aspirin to all those with high-risk ET. In those with very high initial platelet counts, greater than 1,500/microL, an acquired Von Willebrand deficit may occur and increase risk for hemorrhagic complications. Because of this, some practitioners may elect to cytoreduce prior to aspirin initiation. Currently, first line cytoreductive therapy is a choice amongst three agents: hydroxyurea, anagrelide, and pegylated interferon. Fortunately, recent trials have clarified some therapeutic nuances of each choice. Hydroxyurea is a traditional treatment for preventing thrombosis in ET since Cortelazzo published on its efficacy in 1995 20 . Later, anagrelide was approved for control of thrombocytosis based on single arm studies 21 . Subsequently, a conundrum was raised as to which agent was superior and preferential in first line therapy. In 2005, Harrison et al. sought to answer this with a randomized comparison of hydroxyurea to anagrelide 22 . In this study, hydroxyurea was found to be superior to anagrelide in terms of rate of arterial thrombosis, serious hemorrhage, and transformation to myelofibrosis, but was inferior in terms of rates of venous thrombosis. Consequently, hydroxyurea became standard first line therapy, with anagrelide being reserved for second line treatment. In 2008, pegylated interferon, a more tolerable form of interferon, was demonstrated to induce hematologic and molecular responses in ET 23, 24 . As an added benefit, pegylated interferon has been shown to retard progression towards fibrosis in some studies 25, 26 however this remains controversial and is an area of ongoing investigation. Currently, it is still unknown whether hydroxyurea or pegylated interferon represents the best initial treatment strategy. The Myeloproliferative Disorders Research Consortium (MPD-RC) is conducting a phase III international study to evaluate the efficacy, safety, and tolerability of hydroxyurea versus pegylated interferon in frontline therapy for ET/PV. (clinicaltrials. gov: NCTO1259817). Additionally, it is important to mention that interferon therapy is safe in pregnancy, unlike hydroxyurea and anagrelide and thus, pegylated interferon is the preferred agent in this patient population or those who wish to become pregnant.
Second line therapy
In those who are intolerant or resistant to initial therapy a therapeutic switch is indicated and is largely guided by first line choices. A common practice is to progress through the first line cytoreductive agents, with no data directing the sequence of therapies. Aspirin is continued throughout if not contraindicated. The duration of therapy is typically lifelong, with the goal of treatment being hemorrhagic and thrombotic risk reduction, as well as retardation of disease progression. For those who are intolerant to or progressed on all approved agents, clinical trials should be considered. Novel therapeutics, particularly JAK inhibitors, offer a valuable addition to the treatment armamentarium and are available via clinical trial for ET. Moreover, other drug classes such as telomerase inhibitors are promising for the future treatment of ET. Often, in those with very proliferative disease (i.e. platelet count >2000 × 10(9)/L), an effective combination therapeutic approach is used. Hydroxyurea and anagrelide, for example, can be used concurrently for optimal cytoreduction and greater tolerability, as the dosage of each is lower in combination than with single agent therapy alone.
Monitoring for progression
A minority of patients progress to myelofibrosis or acute myeloid leukemia (AML) 27 . Practitioners should pay careful attention to the patient's symptom burden, peripheral blood counts, and cytogenetic analysis for clues indicating progression. The development of increased constitutional symptoms such as progressive splenomegaly, fever, weight loss, early satiety, and bone pain in conjunction with a trend towards either new cytopenia or increased rate of 
Conclusion
In evaluating cases of thrombocythemia, it is essential to exclude both reactive processes and other chronic myeloid disorders prior to making the diagnosis of essential thrombocythemia. Mutational analysis is helpful in making the diagnosis and the well-informed clinician can consider JAKV617F and if wild type subsequent MPL, and CALR assessment in new patient evaluations. In ET patients with high-risk disease, aspirin plus either hydroxyurea versus pegylated interferon is the standard first line therapy. Anagrelide is appropriate as an adjunct to therapy or for second line usage. Clinical trial enrollment is imperative to answer outstanding questions regarding safety, tolerability, and efficacy of alternative therapies
